CIBC Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.83M | Sell |
29,342
-130
| -0.4% | -$39.2K | 0.02% | 421 |
|
|
2026
Q1 | $9.75M | Sell |
29,472
-360
| -1% | -$123K | 0.02% | 379 |
|
|
2025
Q4 | $11.9M | Buy |
29,832
+24,334
| +443% | +$10.8M | 0.03% | 335 |
|
|
2025
Q3 | $2.51M | Buy |
5,498
+40
| +0.7% | +$16.3K | 0.01% | 541 |
|
|
2025
Q2 | $1.78M | Buy |
5,458
+36
| +0.7% | +$9.96K | 0.01% | 588 |
|
|
2025
Q1 | $1.46M | Buy |
5,422
+288
| +6% | +$74K | ﹤0.01% | 623 |
|
|
2024
Q4 | $1.21M | Buy |
5,134
+651
| +15% | +$171K | ﹤0.01% | 657 |
|
|
2024
Q3 | $1.23M | Buy |
4,483
+234
| +6% | +$60.9K | ﹤0.01% | 656 |
|
|
2024
Q2 | $1.03M | Buy |
4,249
+227
| +6% | +$35.8K | ﹤0.01% | 662 |
|
|
2024
Q1 | $601K | Buy |
4,022
+8
| +0.2% | +$1.33K | ﹤0.01% | 711 |
|
|
2023
Q4 | $768K | Sell |
4,014
-308
| -7% | -$52.5K | ﹤0.01% | 686 |
|
|
2023
Q3 | $765K | Buy |
4,322
+128
| +3% | +$24.4K | ﹤0.01% | 674 |
|
|
2023
Q2 | $797K | Buy |
4,194
+3
| +0.1% | +$595 | ﹤0.01% | 679 |
|
|
2023
Q1 | $840K | Buy |
4,191
+84
| +2% | +$17.7K | ﹤0.01% | 678 |
|
|
2022
Q4 | $976K | Sell |
4,107
-1,199
| -23% | -$256K | ﹤0.01% | 671 |
|
|
2022
Q3 | $1.06M | Buy |
5,306
+14
| +0.3% | +$2.67K | ﹤0.01% | 660 |
|
|
2022
Q2 | $772K | Sell |
5,292
-95
| -2% | -$13.5K | ﹤0.01% | 693 |
|
|
2022
Q1 | $880K | Buy |
5,387
+28
| +0.5% | +$4.27K | ﹤0.01% | 724 |
|
|
2021
Q4 | $909K | Buy |
5,359
+581
| +12% | +$108K | ﹤0.01% | 715 |
|
|
2021
Q3 | $902K | Buy |
4,778
+427
| +10% | +$80.1K | ﹤0.01% | 700 |
|
|
2021
Q2 | $738K | Buy |
4,351
+11
| +0.3% | +$1.61K | ﹤0.01% | 740 |
|
|
2021
Q1 | $613K | Buy |
4,340
+161
| +4% | +$24.2K | ﹤0.01% | 752 |
|
|
2020
Q4 | $543K | Hold |
4,179
| – | – | ﹤0.01% | 730 |
|
|
2020
Q3 | $608K | Buy |
4,179
+103
| +3% | +$14.6K | ﹤0.01% | 672 |
|
|
2020
Q2 | $604K | Hold |
4,076
| – | – | ﹤0.01% | 650 |
|
|
2020
Q1 | $444K | Sell |
4,076
-699
| -15% | -$80.7K | ﹤0.01% | 654 |
|
|
2019
Q4 | $550K | Buy |
4,775
+521
| +12% | +$51.9K | ﹤0.01% | 708 |
|
|
2019
Q3 | $342K | Sell |
4,254
-273
| -6% | -$21.6K | ﹤0.01% | 790 |
|
|
2019
Q2 | $328K | Hold |
4,527
| – | – | ﹤0.01% | 822 |
|
|
2019
Q1 | $423K | Buy |
4,527
+560
| +14% | +$46.8K | ﹤0.01% | 755 |
|
|
2018
Q4 | $289K | Sell |
3,967
-15
| -0.4% | -$1.15K | ﹤0.01% | 792 |
|
|
2018
Q3 | $349K | Sell |
3,982
-114
| -3% | -$11.5K | ﹤0.01% | 797 |
|
|
2018
Q2 | $403K | Buy |
4,096
+465
| +13% | +$46.1K | ﹤0.01% | 768 |
|
|
2018
Q1 | $432K | Buy |
3,631
+541
| +18% | +$69.7K | ﹤0.01% | 743 |
|
|
2017
Q4 | $393K | Hold |
3,090
| – | – | ﹤0.01% | 753 |
|
|
2017
Q3 | $363K | Buy |
3,090
+313
| +11% | +$26.7K | ﹤0.01% | 753 |
|
|
2017
Q2 | $221K | Buy |
+2,777
| New | +$177K | ﹤0.01% | 885 |
|
|
2016
Q4 | – | Sell |
-4,463
| Closed | -$303K | – | 961 |
|
|
2016
Q3 | $303K | Buy |
4,463
+344
| +8% | +$24.3K | ﹤0.01% | 777 |
|
|
2016
Q2 | $229K | Buy |
4,119
+46
| +1% | +$2.9K | ﹤0.01% | 829 |
|
|
2016
Q1 | $256K | Buy |
4,073
+422
| +12% | +$28.1K | ﹤0.01% | 794 |
|
|
2015
Q4 | $344K | Buy |
3,651
+475
| +15% | +$44K | ﹤0.01% | 739 |
|
|
2015
Q3 | $255K | Buy |
3,176
+609
| +24% | +$67.7K | ﹤0.01% | 795 |
|
|
2015
Q2 | $308K | Buy |
2,567
+314
| +14% | +$37.5K | ﹤0.01% | 781 |
|
|
2015
Q1 | $235K | Buy |
+2,253
| New | +$228K | ﹤0.01% | 858 |
|
Other funds holding ALNY
CIBC Asset Management's ALNY Position: Q2 2026 in Review
CIBC Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.44% in Q2 2026, selling an estimated $39.2K and leaving 29,342 shares worth $8.83M. The position accounts for 0.02% of the portfolio, ranked #421.
CIBC Asset Management first reported a position in ALNY in Q1 2015 and has held it in 44 quarters since. The position peaked at $11.9M in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- CIBC Asset Management held 29,342 shares of Alnylam Pharmaceuticals worth $8.83M as of Q2 2026.
- CIBC Asset Management sold 130 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $39.2K.
- Alnylam Pharmaceuticals made up 0.02% of CIBC Asset Management's portfolio in Q2 2026, its #421 holding.
- CIBC Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and has held it in 44 quarters since.
- CIBC Asset Management's Alnylam Pharmaceuticals position peaked at $11.9M in Q4 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.